0.00Open0.00Pre Close0 Volume0 Open Interest1.50Strike Price0.00Turnover0.00%IV84.06%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier60DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Atara Biotherapeutics Stock Discussion
Should see increased acitivity soon as all these large investors have interest in this comp...
good buy
Atara Biotherapeutics Announces $36 Million Registered Direct Offering
Atara Biotherapeutics (Nasdaq: ATRA) has announced a $36 million registered direct offering of common stock and pre-funded warrants. The offering, priced at $8.25 per share, represents a 15% premium to Atara's 7-day volume-weighted average price. Participants include existing top institutional investors and a new strategic investor from a large public biotechnology company. The proceeds wi...
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
Atara Biotherapeutics (Nasdaq: ATRA) reported Q2 2024 financial results and operational progress. Key highlights include:
1. Tab-cel® U.S. BLA accepted under Priority Review with PDUFA date of January 15, 2025.
2. ATA3219 studies in Lupus Nephritis and Severe Systemic Lupus Erythematosus to start Q4 2024; initial data expected mid-2025.
3. ATA3...
Atara Biotherapeutics- Bla Acceptance Triggers $20 Mln Milestone Payment With Additional $60 Mln Milestone if Approved by FDA
No comment yet